Skip to main content
. 2021 Sep 12;12(19):2574–2584. doi: 10.1111/1759-7714.14141

FIGURE 4.

FIGURE 4

Gefitinib and anlotinib synergistically inhibited the Akt and ERK signaling pathways. After 48 h treatment with gefitinib, anlotinib, and gefitinib plus anlotinib, the key proteins involved in the EGFR and VEGFR2 downstream signaling pathways such as VEGFR2, p‐VEGFR2, EGFR, p‐EGFR, Akt, p‐Akt, ERK1/2, and p‐ERK1/2, were analyzed by Western blot analysis